The incidence of cardiac toxicity induced by immune checkpoint inhibitors and the construction of precision diagnosis and treatment system

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037424

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac toxicity induced by immune checkpoint inhibitors

Interventions

Patients with cardiotoxicity vs patients without cardiotoxicity:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged >=18 years; 2. All patients in the research center who received immunocheckpoint inhibitor treatment; 3. Patients diagnosed as tumors by histological or cytopathological diagnosis; 4. Predicted the life cycle of > for 1 year; 5, KPS > 60; 6. Volunteer for the experiment.

Exclusion criteria

Exclusion criteria: 1. Severe liver and kidney dysfunction; 2. LVEF < 40% for severe cardiac insufficiency; 3. Hemodynamically unstable arrhythmia; 4. Severe hypertension has not been controlled; 5. Symptomatic valvular heart disease; 6. Pregnancy or lactation; 7. Poor compliance; 8. Participated in the rest of the experiments three months before this experiment; 9. The researcher considers it inappropriate to participate in the experiment.

Design outcomes

Primary

Measure	Time frame
myocardial enzyme;UCG;ST2;BNP;ECG;Noninvasive cardiopulmonary testing;	—

Secondary

Measure	Time frame
blood routine;Biochemicaltests;coagulation function;	—

Countries

China

Contacts

Public ContactCheng Leilei

Zhongshan Hospital, Fudan University

cheng.leilei@zs-hospital.sh.cn+86 13916866296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026